Eisai’s Phase III trial of lenvatinib meets primary endpoint of PFS in thyroid cancer patients
When compared to placebo, lenvatinib showed statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). According to the preliminary safety analysis,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.